CN Patent

CN103339126B — 式(i)化合物的固态形式及其药物组合物、剂型和使用方法

Assigned to Portola Pharmaceuticals LLC · Expires 2016-06-29 · 10y expired

What this patent protects

本发明涉及新型无水结晶形式的[(5-氯噻吩-2-基磺酰基氨甲酰基)-(4-(6-氟-7-(甲基氨基)-2,4-二氧代-1,2-二氢喹唑啉-3(4H)-基)苯基)氨基钾盐，及其在治疗或预防动物(具体是人类)中具有血小板ADP受体抑制(具体是P2Y 12 抑制)的病症或障碍中的用途。本发明还涉及制备这种新型结晶形式的方法。本发明还涉及该新型结晶形式的固体口服制剂、它的制备及其用途。

USPTO Abstract

本发明涉及新型无水结晶形式的[(5-氯噻吩-2-基磺酰基氨甲酰基)-(4-(6-氟-7-(甲基氨基)-2,4-二氧代-1,2-二氢喹唑啉-3(4H)-基)苯基)氨基钾盐，及其在治疗或预防动物(具体是人类)中具有血小板ADP受体抑制(具体是P2Y 12 抑制)的病症或障碍中的用途。本发明还涉及制备这种新型结晶形式的方法。本发明还涉及该新型结晶形式的固体口服制剂、它的制备及其用途。

Drugs covered by this patent

benzgalantamine-gluconate (BENZGALANTAMINE GLUCONATE)

Patent Metadata

Patent number: CN103339126B
Jurisdiction: CN
Classification: —
Expires: 2016-06-29
Drug substance claim: No
Drug product claim: No
Assignee: Portola Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.